The RNA targeted therapeutics market involves developing drugs that target the messenger RNA (mRNA) of certain genes associated with diseases. RNA targeted drugs modulate gene expression by controlling mRNA function through mechanisms like RNA interference (RNAi) and antisense oligonucleotides. Conditions like cancer, cardiovascular diseases, metabolic disorders and genetic diseases are actively being researched for RNA targeted therapies.
The RNA targeted therapeutics market is estimated to be valued at USD 1.34 Bn in 2024 and is expected to reach USD 11.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 35.2% from 2024 to 2031.
The market is driven by the growing prevalence of chronic diseases globally and the need for more effective treatment options. RNA targeted drugs have potential to revolutionize disease management by precisely controlling gene functions at the mRNA level with fewer side effects than conventional drugs.
Key players operating in the RNA targeted therapeutics market are Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, Benitec Biopharma, Biogen, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, miRNA Therapeutics, Quark Pharmaceuticals, and Regulus Therapeutics.
These players are focusing on developing novel RNA interference (RNAi) therapies for various disease conditions. The market provides numerous lucrative opportunities for players due to the large unmet need of treating chronic diseases. Technological advances are further expanding the therapeutic applications of RNA targeting drugs. There is a growing R&D on using RNA Targeted Therapeutics Market for conditions beyond hepatocytes like glioblastoma and amyloid diseases.North America dominates the global RNA targeted therapeutics market currently. However, Asia Pacific is expected to provide high growth opportunities during the forecast period. Factors such as rising healthcare investments, growing geriatric population, and increasing collaborations between international drugmakers and local players are fueling the market expansion.
Market Drivers The rising prevalence of chronic diseases globally is a major factor driving the growth of the RNA targeted therapeutics market. According to WHO, chronic diseases accounted for over 70% of all deaths worldwide in 2020. RNA targeting drugs have potential to treat various disease pathways associated with chronic conditions. Additionally, growing R&D investments from pharmaceutical companies and increasing clinical trials are further supporting the market growth.
PEST Analysis
Political: The regulatory policies on clinical trials and drug approvals have an impact on this market. Stringent regulations have increased the approval timelines and costs.
Economic: Changes in the global and regional economic conditions influence the spending on healthcare and pharmaceutical R&D. Economic slowdowns may reduce the funding available for developing novel RNA targeted therapeutics.
Social: The rising prevalence of cancer, genetic disorders and infectious diseases drives social demand for more effective treatment options. Growing awareness about personalized medicine is supporting the development of RNA targeting drugs.
Technological: Advancements in RNA sequencing, siRNA/miRNA design tools, drug delivery systems are enabling the development of more specific and potent RNA targeted drugs. CRISPR technology is opening new avenues for modifying gene expressions.
Geographical Concentration of Market ValueNorth America currently accounts for the largest share of the global RNA targeted therapeutics market in terms of value, led by extensive R&D activities in the US. Presence of major pharmaceutical companies and biotech firms, rise in funding for precision medicine research, and supportive regulatory environment have strengthened North America’s leadership position. Europe is the second largest regional market, whereas Asia Pacific market is growing at a faster pace led by China, India and Japan.
Fastest Growing Regional MarketAsia Pacific market is poised to showcase fastest growth over the forecast period among all regions. Increasing government investments in clinical research, rising healthcare spending, growing incidence of chronic diseases and emergence of domestic pharmaceutical players are some of the key factors driving the growth. China’s massive population size and focus on biologics offer lucrative opportunities. Favorable regulatory framework and tax incentives are attracting global players to establish manufacturing and R&D facilities in Asia Pacific countries to tap the growth potential.
Get this Report in Japanese Language: RNA標的治療薬市場
Get this Report in Korean Language: RNA 표적 치료제 시장
Author Bio:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
